TTY Biopharm Co Ltd

TTY Biopharm maintains a strong liquidity position, with a current ratio of 2.28 and cash and equivalents of TWD 1.26 billion, which supports its short-term obligations. The company's debt-to-equity ratio is 0.17, indicating a conservative capital structure with limited leverage. Free cash flow of TWD 646 million suggests the company is generating sufficient cash to fund operations and potentially reinvest in growth. Profitability metrics show a return on equity (ROE) of 21.54% and a return on assets (ROA) of 13.74%, both of which exceed the typical thresholds for the pharmaceutical industry. The company's operating margin is 26.13% (calculated from operating income of TWD 1.69 billion and revenue of TWD 6.45 billion), which is strong and suggests efficient cost management. Geographically, TTY Biopharm's revenue is concentrated in its domestic market, with no disclosed international segments. The company's exposure to a single market may increase its vulnerability to local economic or regulatory changes. No material revenue diversification is evident from the available data. The company's growth trajectory is positive, with a revenue of TWD 6.45 billion in the latest period. While no forward-looking revenue guidance is provided, the company's strong cash flow and profitability suggest a stable growth outlook. The capital expenditure of TWD -151 million indicates a reduction in investment in physical assets, which may reflect a shift toward cost optimization or a mature product portfolio. Risk factors are limited, with low liquidity and dilution risk identified. No immediate filing-based liquidity or dilution flags were detected, and the company's capital structure remains stable. The absence of dilution risk is supported by the fact that basic and diluted shares outstanding are equal, indicating no near-term dilution pressure. Recent events include analyst estimates that suggest a mean price target of TWD 90.00, with a median of TWD 90.00 and a recommendation mean of 2.50 (indicating a "hold" consensus). No recent filings or transcripts have been disclosed that would suggest material changes in the company's operations or strategy.